ALCON INC
Alcon researches, develops, manufactures, distributes and sells eye care products for consumers, patients, surgeons and other eye care professionals. Its two businesses are Surgical and Vision Care. Surgical offers implantable products, consumables and equipment for cataract, vitreoretinal, refractive laser and glaucoma procedures, along with related services, training and technical support. Vision Care includes daily disposable, reusable and color-enhancing contact lenses, plus ocular health products for dry eye, allergies, glaucoma and contact lens care, as well as ocular vitamins and redness relievers. Alcon makes money by selling these products and related surgical services, and supports customers with education, training and technical assistance. It operates in 56 countries and serves consumers and patients in over 140 countries and territories. Alcon is headquartered in Geneva, Switzerland.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ALC in the last 30 days.
See all $ALC insider activity →Needham reaffirmed its Buy rating for Alcon and kept its price target at $98, suggesting a 65.8% upside from the Oct 30 close of $59.10. Analysts' recent price targets for Alcon range from $70 to $98.
Needham reaffirmed a Buy rating on Alcon with a $98 price target, suggesting 75.8% upside from the Oct 20 close. The target is based on strong growth potential from the Neurotech acquisition and robust financial projections, including mid-single digit revenue growth and double-digit EPS growth.
Alcon (ALC) acquired Neurotech Pharmaceuticals for $550M, gaining ENCELTO, the only FDA-approved treatment for adult MacTel Type 2. Alcon expects modest sales growth and slight EPS dilution in 2027, with accretion thereafter, according to the company.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALC (ALCON INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ALC coverage spans financial news, regulation and technology.
Analyst maintains bullish stance, suggesting upside potential.
Analyst upgrade and higher price target suggest potential upside.
The deal is accretive after 2027 and expands Alcon's product line, likely supporting the stock.
The approval introduces a new revenue stream in the consumer eye‑care market.
Potential revenue pressure from discounted Medicaid pricing.
AlphAI scores every news story that mentions ALC with an AI model for sentiment and relevance, and aggregates insider trades from ALCON INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Needham reaffirmed its Buy rating for Alcon and kept its price target at $98, suggesting a 65.8% upside from the Oct 30 close of $59.10. Analysts' recent price targets for Alcon range from $70 to $98.
1 min readNeedham reaffirmed a Buy rating on Alcon with a $98 price target, suggesting 75.8% upside from the Oct 20 close. The target is based on strong growth potential from the Neurotech acquisition and robust financial projections, including mid-single digit revenue growth and double-digit EPS growth.
1 min readAlcon (ALC) acquired Neurotech Pharmaceuticals for $550M, gaining ENCELTO, the only FDA-approved treatment for adult MacTel Type 2. Alcon expects modest sales growth and slight EPS dilution in 2027, with accretion thereafter, according to the company.
2 min readAlcon's BRYTLY Redness Reliever Eye Drops received FDA approval, reducing redness in a minute and lasting up to 12 hours. The product will expand Alcon's consumer eye care portfolio and be available nationwide. According to Alcon, BRYTLY is clinically proven to be safe and effective, with low risk of rebound redness.
2 min readThe Trump administration announced MFN pricing deals with nine mid-sized pharmaceutical manufacturers, including Teva Pharmaceuticals and Sun Pharma, to lower drug costs for Medicaid. The companies committed to $19.6B in U.S. investments and ingredient donations to SAPIR. Details on discounts and exemptions from future mandates remain unclear.
3 min readAlcon has launched Precision7, a weekly contact lens, to improve patient compliance. According to the company, 80% of patients found the lens comfortable for 16 hours daily, with a 9/10 rating for vision and comfort after seven days. Illume Eyecare's Adele Jefferies noted positive initial feedback, suggesting it could be a good option for new wearers due to its simple replacement routine.
2 min readBernstein recommends Sonova (CHF 275 PT) and Alcon (CHF 76.15 PT) as top European medtech picks for H2, citing strong growth prospects and attractive valuations. Sonova is favored for short-term gains, while Alcon is seen as a long-term compounder. Bernstein's estimates for both companies are above consensus.
2 min readAlcon has warned that a US proposal may lead companies to leave Europe. Novo Holdings and international funds are investing DKK 60 million in a new Danish biotech company, highlighting growth potential in the sector.
1 min readBill Ackman's Pershing Square increased stakes in Visa, Mastercard, Netflix, S&P Global, Intercontinental Exchange, and Alcon, while reducing Amazon and exiting Alphabet. Ackman believes these companies will benefit from AI, citing their proprietary data and strong market positions. Pershing Square reported a -12.6% return in the first half of 2026, lagging the S&P 500. Intercontinental Exchange reported $2.7B in Q2 revenue and raised full-year guidance.
3 min readOptometrist Malik shares her experience with toric contact lenses, emphasizing patient feedback and lifestyle conversations to identify suitable candidates. She encourages practitioners to ask questions and involve the entire practice team in the process. Malik also highlights the importance of early introduction of toric lenses for better patient adaptation. Alcon's WATERINNOVATIONS toric portfolio now supports a broader range of astigmatic patients with extended parameters.
2 min read
